Singapore markets close in 19 minutes
Straits Times Index
3,222.79 +15.80 (+0.49%) Nikkei
31,857.62 -14.90 (-0.05%) Hang Seng
17,809.66 +436.63 (+2.51%) FTSE 100
7,640.83 +38.98 (+0.51%) Bitcoin USD
27,079.66 +674.69 (+2.56%) CMC Crypto 200
583.09 +18.30 (+3.24%)
ABBV Jan 2024 230.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 09:41AM EDT. Market open.
| Previous close | 69.95 |
| Open | 69.95 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 230.00 |
| Expiry date | 2024-01-19 |
| Day's range | 69.95 - 69.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksTop Analyst Reports for Oracle, AbbVie & Lowe's
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), AbbVie Inc. (ABBV) and Lowe's Companies, Inc. (LOW).
ZacksIs It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ZacksAbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio
© 2023 Yahoo. All rights reserved.
